22.70Open22.70Pre Close0 Volume50 Open Interest145.00Strike Price0.00Turnover303.13%IV50.06%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry22.70Extrinsic Value100Contract SizeAmericanOptions Type-0.1457Delta0.0012Gamma10.79Leverage Ratio-0.8687Theta-0.0380Rho-1.57Eff Leverage0.1499Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet